164 related articles for article (PubMed ID: 21481731)
1. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer: in regard to Arcangeli C, et al. (Int J Radiat Oncol Biol Phys 2010;78:11-18).
Vogelius IR; Bentzen SM
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):316; author reply 316-7. PubMed ID: 21481731
[No Abstract] [Full Text] [Related]
2. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer.
Arcangeli G; Saracino B; Gomellini S; Petrongari MG; Arcangeli S; Sentinelli S; Marzi S; Landoni V; Fowler J; Strigari L
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):11-8. PubMed ID: 20047800
[TBL] [Abstract][Full Text] [Related]
3. In regard to Fiorino et al.: Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer (Int J Radiat Oncol Biol Phys 2003;57:953-962).
Bauman G; Rodrigues G
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):912-4; author reply 914-5. PubMed ID: 15183497
[No Abstract] [Full Text] [Related]
4. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions: in regard to Morikawa and Roach III (Int J Radiat Oncol Biol Phys 2011 May 1;80:6-16).
Revannasiddaiah S; Gupta MK; Seam RK; Madabhavi I
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1318; author reply 1318. PubMed ID: 22385711
[No Abstract] [Full Text] [Related]
5. Volumetric modulated arc therapy for delivery of prostate radiotherapy: in regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996-1001).
Ost P; Fonteyne V; De Neve W; De Gersem W; De Wagter C; Vandecasteele K; Duprez F; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1286; author reply 1287. PubMed ID: 19251105
[No Abstract] [Full Text] [Related]
6. CTV margins in prostate cancer irradiation. In regard to Teh et al.: IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease (Int J Radiat Oncol Biol Phys 2003;56:184-191).
Macias V
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):320-1; author reply 321-2. PubMed ID: 15093933
[No Abstract] [Full Text] [Related]
7. Does image-guided radiotherapy (IG-IMRT) improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT: In regard to Chung et al. (Int J Radiat Oncol Biol Phys 2008. In press).
Jothybasu KS; Bahl A; Subramani V; Sharma DN; Rath GK
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1273; author reply 1273. PubMed ID: 18954726
[No Abstract] [Full Text] [Related]
8. In regard to Purdy JA, Michalski JM. Does the evidence support the enthusiasm over 3D conformal radiation therapy and dose escalation in the treatment of prostate cancer? Int J Radiat Oncol Biol Phys 2001;51:867-870.
Levitt SH; Khan FM
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):1085; author reply 1085-6. PubMed ID: 12095577
[No Abstract] [Full Text] [Related]
9. A marginal issue: in regard to Wolden et al. (Int J Radiat Oncol Biol Phys 2005;61:1432-1438).
Scarbrough TJ; Thomas CR
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):647-8; author reply 648-9. PubMed ID: 16168860
[No Abstract] [Full Text] [Related]
10. Randomized trial of high- and low-source strength (125)I prostate seed implants: In regard to Narayana et al. (Int J Radiat Oncol Biol Phys 2005;61:44-51).
Moerland MA; Battermann JJ
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):941-2. PubMed ID: 15936582
[No Abstract] [Full Text] [Related]
11. Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation" Int J Radiat Oncol Biol Phys 2009;75:1290-1296).
Wolmark N; Curran WJ; Vicini F; White J; Costantino JP; Arthur D; Kuske R; Rabinovitch R; Julian TB; Parda DS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):317; author reply 318. PubMed ID: 20394863
[No Abstract] [Full Text] [Related]
12. In regards to Wallner et al: (125)I versus (103)PD for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial (Int J Radiat Oncol Biol Phys 2003;57:1297-1303).
Lee WR
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):319; author reply 319-20. PubMed ID: 15093929
[No Abstract] [Full Text] [Related]
13. Response to "Dosimetric study of pelvic radiotherapy for high-risk prostate cancer." (Int J Radiat Oncol Biol Phys 2009;75:994-1002).
Dimitroyannis DA
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):315; author reply 316. PubMed ID: 20708490
[No Abstract] [Full Text] [Related]
14. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer: in regard to Diez P, et al. (Int J Radiat Oncol Biol Phys 2010;77:1066-1071).
Williams SG
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):639; author reply 639-40. PubMed ID: 21549251
[No Abstract] [Full Text] [Related]
15. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions: in regard to Lawton et al. (Int J Radiat Oncol Biol Phys 2007;69:646-655.).
Millar J; Boyd R; Sutherland J
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):316; author reply 316. PubMed ID: 18406900
[No Abstract] [Full Text] [Related]
16. Modeling prostate cancer: in regards to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401).
Wang JZ; Mayr NA; Li XA; Stewart RD
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):309-10; author reply 310-1. PubMed ID: 15629636
[No Abstract] [Full Text] [Related]
17. In regard to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391-401): Incorporating clinical measurements of hypoxia into tumor control modeling of prostate cancer: implications for the alpha/beta ratio.
Orton CG
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1637; author reply 1637-9. PubMed ID: 15050348
[No Abstract] [Full Text] [Related]
18. Dose-rate effects when estimating risks for second malignancies: in regard to Fontenot et al (Int J Radiat Oncol Biol Phys 2009;74:616-622).
Paganetti H; Athar BS; Bednarz B
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1624; author reply 1624-5. PubMed ID: 19931743
[No Abstract] [Full Text] [Related]
19. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer.
Arcangeli G; Fowler J; Gomellini S; Arcangeli S; Saracino B; Petrongari MG; Benassi M; Strigari L
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1013-21. PubMed ID: 20447774
[TBL] [Abstract][Full Text] [Related]
20. A mixed-modality 3d-conformal accelerated partial breast irradiation technique using opposed mini-tangent photon fields and en face electrons to minimize the lung exposure to radiation: in regard to Jain et al. (Int J Radiat Oncol Biol Phys 2009;75:82-88).
Bourgier C; Marsiglia H; Taghian A
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):956-7; author reply 957. PubMed ID: 20159367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
